Press release
Systemic Sclerosis Pipeline Assessment 2024: Clinical Trials, FDA, EMA, PDMA Approvals, Therapies, MOA, ROA, and Companies by DelveInsight | GS-248, KHK4827, Paquinimod, Inebilizumab, Nemolizumab, RO7303509, Treprostinil Diethanolamine
(New York, USA) DelveInsight's, "Systemic Sclerosis Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Systemic Sclerosis pipeline landscape. It covers the Systemic Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.Request a sample and discover the recent advances in Systemic Sclerosis Treatment Drugs @ Systemic Sclerosis Pipeline Report- https://www.delveinsight.com/report-store/systemic-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
In the Systemic Sclerosis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Systemic Sclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key Takeaways from the Systemic Sclerosis Pipeline Report
• DelveInsight's Systemic Sclerosis pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Systemic Sclerosis treatment.
• Leading Systemic Sclerosis companies working in the Market include Eicos Sciences, Beijing Continent Pharmaceutical, Kyowa Kirin, Cytori therapeutics, Corbus Pharmaceuticals, Zenyaku Kogyo, Sanofi, Bayer, ASKA Pharmaceutical, Emerald Health Pharmaceuticals, United Therapeutics, Cumberland Pharmaceuticals, ILTOO Pharma, Horizon Pharmaceuticals, Janssen Biotech, Gesynta Pharma, Certa Therapeutics, Pfizer, Vicore Pharma, Seagen, CSL Behring, arGentis Pharmaceuticals, Mitsubishi Tanabe Pharma, Kadmon Pharmaceuticals, GlaxoSmithKline, Bristol-Myers Squibb, Camurus, Pfizer, Regeneron Pharmaceuticals, Castle Creek Biosciences, Talaris Therapeutics, Viela Bio, Formation Biologics, Horizon Therapeutics, Chemomab therapeutics, AnaMar, Atlantic Healthcare, D&D Pharmatech, Acceleron Pharma, Riptide Bioscience, Timber Pharmaceuticals, Tvardi Therapeutics, Accuitis Pharmaceuticals, AKL Research and Development, iBio, Blade Therapeutics, Cantargia, BriaCell Therapeutics, Leadiant Biosciences, and others.
• Promising Systemic Sclerosis Pipeline Therapies in the various stages of development include GS-248, KHK4827, Paquinimod, Inebilizumab, Nemolizumab, RO7303509, Treprostinil Diethanolamine, and others.
• On September 2023, Horizon Pharma Ltd announced a study of phase 2 clinical trials for HZN-825 BID. All participants who complete the Double-blind Treatment Period (Week 52) will be eligible to enter a 52-week extension trial (HZNP-HZN-825-302, NCT05626751). Participants not entering the extension trial will participate in a Safety Follow-up Visit 4 weeks after the last dose of trial drug.
• On September 2023, Hospital for Special Surgery, New York announced a study of phase 2 clinical trials for Belimumab, and MMF. After patients maintain a stable dose of Mycophenolate Mofetil (MMF) for at least 1 month, they will be randomized to treatment with either Belimumab & Rituximab or placebo. Patients in both groups will be on background MMF for the entirety of the study. Belimumab will be administered subcutaneously and Rituximab intravenously.
Systemic Sclerosis Overview
Scleroderma, also known as Systemic Sclerosis, progressive systemic sclerosis or the CREST syndrome, is a chronic skin disorder that affects the skin, connective tissues and other internal organs. The disorder takes place sin humans, when the immune system causes the body to make the protein collagen, an important component of the skin, in huge amounts.
Find out more about Systemic Sclerosis Therapeutics Assessment @ Systemic Sclerosis Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/systemic-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Systemic Sclerosis Emerging Drugs Profile
• Iloprost: Eicos Sciences
• ECCS 50: Cytori therapeutics
• Lenabasum (JBT-101): Corbus Pharmaceuticals
• EHP-101: Emerald Health Pharmaceuticals
Systemic Sclerosis Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing the Systemic Sclerosis therapies. The Systemic Sclerosis companies which have their Systemic Sclerosis drug candidates in the most advanced stage, i.e. Phase III include, Eicos Sciences.
Learn more about the emerging Systemic Sclerosis Pipeline Therapies @ Systemic Sclerosis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/systemic-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Systemic Sclerosis Pipeline Report
• Coverage- Global
• Systemic Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Systemic Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Systemic Sclerosis Companies- Eicos Sciences, Beijing Continent Pharmaceutical, Kyowa Kirin, Cytori therapeutics, Corbus Pharmaceuticals, Zenyaku Kogyo, Sanofi, Bayer, ASKA Pharmaceutical, Emerald Health Pharmaceuticals, United Therapeutics, Cumberland Pharmaceuticals, ILTOO Pharma, Horizon Pharmaceuticals, Janssen Biotech, Gesynta Pharma, Certa Therapeutics, Pfizer, Vicore Pharma, Seagen, CSL Behring, arGentis Pharmaceuticals, Mitsubishi Tanabe Pharma, Kadmon Pharmaceuticals, GlaxoSmithKline, Bristol-Myers Squibb, Camurus, Pfizer, Regeneron Pharmaceuticals, Castle Creek Biosciences, Talaris Therapeutics, Viela Bio, Formation Biologics, Horizon Therapeutics, Chemomab therapeutics, AnaMar, Atlantic Healthcare, D&D Pharmatech, Acceleron Pharma, Riptide Bioscience, Timber Pharmaceuticals, Tvardi Therapeutics, Accuitis Pharmaceuticals, AKL Research and Development, iBio, Blade Therapeutics, Cantargia, BriaCell Therapeutics, Leadiant Biosciences, and others.
• Systemic Sclerosis Pipeline Therapies- GS-248, KHK4827, Paquinimod, Inebilizumab, Nemolizumab, RO7303509, Treprostinil Diethanolamine, and others.
Dive deep into rich insights for new drugs for Systemic Sclerosis Treatment Market, Visit @ Systemic Sclerosis Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/systemic-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Introduction
2. Executive Summary
3. Systemic Sclerosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Iloprost: Eicos Sciences
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. EHP-101: Emerald Health Pharmaceuticals
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I)
13. VIB7734: Viela Bio
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Systemic Sclerosis Key Companies
17. Systemic Sclerosis Key Products
18. Systemic Sclerosis- Unmet Needs
19. Systemic Sclerosis- Market Drivers and Barriers
20. Systemic Sclerosis- Future Perspectives and Conclusion
21. Systemic Sclerosis Analyst Views
22. Systemic Sclerosis Key Companies
23. Appendix
For further information on the Systemic Sclerosis pipeline therapeutics, reach out to Systemic Sclerosis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/systemic-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Trending Reports:
• Acute Pain Market: https://www.delveinsight.com/report-store/acute-pain-market
• Alopecia Aerata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Neuromodulation Devices Market: https://www.delveinsight.com/report-store/neuromodulation-devices-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Parkinson's Disease Market: https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Brain Cancer Market: https://www.delveinsight.com/report-store/brain-cancer-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Biliary Tumor Market: https://www.delveinsight.com/report-store/biliary-tumor-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market
• Emesis Market: https://www.delveinsight.com/report-store/emesis-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/hearing-aid-devices-market
• Reactive Arthritis Market: https://www.delveinsight.com/report-store/reactive-arthritis-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Airway Stent Market Market: https://www.delveinsight.com/report-store/airway-stent-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Asphyxia Market: https://www.delveinsight.com/report-store/asphyxia-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Vitamin A Deficiency Market: https://www.delveinsight.com/report-store/vitamin-a-deficiency-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Systemic Sclerosis Pipeline Assessment 2024: Clinical Trials, FDA, EMA, PDMA Approvals, Therapies, MOA, ROA, and Companies by DelveInsight | GS-248, KHK4827, Paquinimod, Inebilizumab, Nemolizumab, RO7303509, Treprostinil Diethanolamine here
News-ID: 3489449 • Views: …
More Releases from DelveInsight Business Research
Spasticity Clinical Pipeline 2025: A Comprehensive Review of 12+ Emerging Therap …
According to DelveInsight's latest analysis, the global Spasticity pipeline features more than 10 active pharmaceutical companies that are advancing over 12 investigational therapies. The report offers a detailed evaluation of clinical trials, mechanisms of action, therapeutic approaches, routes of administration, and major developmental activities shaping the Spasticity treatment landscape.
DelveInsight's report, "Spasticity Pipeline Insight, 2025," delivers an extensive overview of the current clinical development environment and the future outlook for the…
Real-World Evidence Solution Market is set to grow at a 8.07% CAGR, reaching USD …
According to DelveInsight, the real-world evidence (RWE) solutions market is expanding rapidly, primarily due to the increasing global burden of chronic diseases and the growing need to improve healthcare outcomes. In addition, advancements in big data analytics, artificial intelligence, and machine learning are enhancing the ability to efficiently process and interpret large-scale real-world datasets. The rising adoption of RWE solutions by pharmaceutical and biotechnology companies - to support drug development,…
Spinal Implants Market is set to grow at a 5.50% CAGR, reaching USD 21.9 billion …
According to DelveInsight's assessment, the rising burden of spinal disorders particularly within the growing elderly population - continues to significantly increase the demand for surgical correction procedures. Alongside this, the surge in sports-related injuries and trauma cases is accelerating the need for advanced implantable spinal solutions. There is also a notable shift toward non-fusion and motion-preserving devices that support spinal flexibility and enhance patient outcomes, especially for younger and more…
Vascular Stents Market is set to grow at a 6.65% CAGR, reaching USD 18.28 billio …
According to DelveInsight's assessment, the rising global burden of cancer is significantly increasing the demand for advanced treatment approaches such as tumor ablation. Minimally invasive ablation techniques are gaining strong traction due to their advantages, including faster recovery times, lower complication risks, and reduced costs compared with traditional surgical procedures. At the same time, continuous improvements in ablation technologies - particularly in radiofrequency, microwave, and cryoablation systems - have enhanced…
More Releases for Systemic
What Is Driving Global Systemic Aspergillosis And Systemic Candidiasis Market Gr …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Systemic Aspergillosis And Systemic Candidiasis Market Size Growth Forecast: What to Expect by 2025?
The market valuation for systemic aspergillosis and systemic candidiasis has experienced consistent upward momentum across recent years, projected to advance from a figure of $7.24 billion in 2024 to reach $7.57 billion by 2025, reflecting…
Transformative Trends Impacting the Systemic Aspergillosis And Systemic Candidia …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Systemic Aspergillosis And Systemic Candidiasis Market Size By 2025?
The growth trend of the systemic aspergillosis and systemic candidiasis market has been steadily ascending in the past few years. The market size will inflate from $7.24 billion in 2024 to $7.59 billion in 2025, indicating…
Systemic Aspergillosis And Systemic Candidasis Market Size by Type, Application, …
According to Market Research Intellect, the global Systemic Aspergillosis And Systemic Candidasis market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The growing prevalence of invasive fungal infections, especially in immunocompromised persons, is propelling the global…
Systemic Aspergillosis and Systemic Candidiasis Treatment Market - Industry Over …
The systemic aspergillosis and systemic candidiasis treatment market is gaining significant attention within the global healthcare and pharmaceutical industries due to the increasing incidence of life-threatening fungal infections among immunocompromised individuals. Both systemic aspergillosis and systemic candidiasis are opportunistic fungal infections, often affecting patients with weakened immune systems due to cancer therapy, organ transplantation, HIV/AIDS, or intensive care treatments.
The systemic aspergillosis and systemic candidiasis treatment market was valued at approximately…
Systemic Aspergillosis and Systemic Candidiasis Market Share, Sales Channels and …
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
The systemic aspergillos is and systemic candidiasis market is expected to reach US$ 8,247.5 million by 2027 from US$ 6,056.3 million in 2019. The market is estimated to grow at a CAGR of 4.0% from 2020 to 2027.
To get sample Copy of the report, along with…
Systemic Aspergillosis and Systemic Candidiasis Treatment Market Insight & Futur …
(Portland, United States): Avail a detailed research offering a comprehensive analysis of the developments, growth outlook, driving factors, and key players of the Systemic Aspergillosis and Systemic Candidiasis Treatment Market in the latest research report added by Big Market Research. The recent research report on the global Systemic Aspergillosis and Systemic Candidiasis Treatment Market presents the latest industry data and future trends, allowing you to recognize the products and end…
